Licensed assets enter the clinic
The latest first-in-human trial initiations include projects licensed in by Gilead and Context.
Arvinas and Pfizer turn away from Ibrance
In first-line breast cancer vepdegestrant will be combined with Pfizer’s investigational CDK4 inhibitor atirmociclib.
Celcuity goes early with its Pfizer cast-off
The company is to start a first-line phase 3 breast cancer trial of gedatolisib, as second-line data approach.
Pfizer moves pivotal assets into the front line
An anti-integrin β6 ADC and a CDK4 inhibitor shoot for bigger markets.
Biocytogen and PTK7 remain hot
First-in-human trial initiations include Biocytogen's DM002 and Day One's DAY301.
ImmunityBio follows through in lung cancer
A new phase 3 study will test Anktiva in PD-(L)1-relapsed lung cancer.
The month ahead: January’s upcoming events
Investors will hope for a JP Morgan buying spree, while readouts could come from Kura, Allogene and MacroGenics.
Conjugates enter their first clinical trials
Two Kelun ADCs and two actinium-based radioconjugates start phase 1.
Another pan-KRAS project enters the clinic
Quanta now has a “G12V-preferring” multi-KRAS asset on its clinical roster.
